EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
Mené sur 222 patients atteints d'un cancer du poumon de stade avancé sans mutation du gène EGFR, cet essai italien compare, du point de vue de la survie globale, l'efficacité de l'erlotinib et du docétaxel en traitement de deuxième ligne
Gefitinib and erlotinib—EGFR tyrosine kinase inhibitors—were the first molecularly targeted drugs used to treat advanced non-small-cell lung cancer (NSCLC). The positive results of BR.21—a phase 3 study comparing erlotinib with placebo in patients with NSCLC in whom first-line or second-line chemotherapy had failed—paved the way for the widespread use of these drugs. When BR.21 was started, EGFR mutations in NSCLC had not yet been identified, therefore the study included molecularly unselected pat ...
The Lancet Oncology , commentaire, 2012